Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 57.0 | +18.8% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | 20.0 | +12.0 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | 6.0 | +500.0% YoY | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. |
| Return on equity | +6.3 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. | |
| Free cash flow margin | -6.41 | +6.8 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | +50.7 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. |
Guidance
7 targets tracked, none judged yet · 7 open · verdicts reflect calls analysed to Q2 FY26.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| FY26 Revenue | Rs. 140-150 crores | Q2 FY26 | Management confirmed they expect to reach somewhere close to the Rs. 140-150 Cr target. | New |
7 of Saakshi Medtech's 7 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 6 more targets are in the full ledger.
Claimed
Qualified
Price
1Y: ₹153.4 on 24 Oct 2025 → ₹365. High ₹380.75 (23 Sept 2026), low ₹151.7 (27 Oct 2025).
Overview
close before → close after
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Guidance
7 targets tracked, none judged yet · 7 open · verdicts reflect calls analysed to Q2 FY26.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| FY26 Revenue | Rs. 140-150 crores | Q2 FY26 | Management confirmed they expect to reach somewhere close to the Rs. 140-150 Cr target. | New |
Claimed
Qualified
The full ledger
A free account opens 5 company ledgers a month. All 7 tracked commitments, with each call’s wording and source.
Call summaries
Saakshi Medtech H1 FY26
Saakshi Medtech reported a strong H1 FY26, with revenue growing 31% YoY to Rs. 58.31 crores and EBITDA improving to 18.71%. This growth was driven by a seven-fold increase in aerospace revenue and a 40% surge in the integrated control system segment. While net profit reached Rs. 6.63 crores, the company saw a decline in cash due to ongoing CAPEX and increased working capital, alongside higher debt for facility expansion.
Read the full callEvery analysed call
Fundamentals
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
Net profit, year on year: +500% (quarter to mar 2026 against mar 2025).
| Line item | Mar 2023 | Sept 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 69 | 61 | 61 | 44 | 48 | 58 | 57 |
| Expenses | 57 | 52 | 50 | 38 | 44 | 48 | 46 |
| Operating profit | 12 | 10 | 10 | 6 | 4 | 11 | 12 |
| Operating margin | 17.0% | 16.0% | 17.0% | 15.0% | 8.0% | 18.0% | 20.0% |
| Other income | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
| Profit before tax | 10 | 7 | 8 | 5 | 2 | 9 | 8 |
| Tax rate | 26.0% | 23.0% | 25.0% | 28.0% | 30.0% | 25.0% | 28.0% |
| Net profit | 7 | 6 | 6 | 3 | 1 | 7 | 6 |
| EPS (₹ per share) | — | 3.14 | 3.40 | 1.95 | 0.71 | 3.76 | 3.21 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 18 | 18 | 18 | 18 |
| Reserves | 27 | 40 | 76 | 80 | 87 | 93 |
| Borrowings | 16 | 20 | 18 | 18 | 24 | 25 |
| Other liabilities | 19 | 31 | 19 | 15 | 19 | 21 |
| Total liabilities | 65 | 93 | 131 | 131 | 148 | 157 |
| Fixed assets | 26 | 34 | 62 | 60 | 76 | 83 |
| Capital work in progress | 0 | 0 | 0 | 13 | 9 | 10 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 39 | 59 | 68 | 58 | 62 | 64 |
| Total assets | 65 | 93 | 131 | 131 | 148 | 157 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 0 | 11 | 11 | 8 | 3 | 18 |
| Cash from investing | -1 | -5 | -11 | -31 | -15 | -25 |
| Cash from financing | 2 | -7 | 2 | 36 | -1 | 6 |
| Net cash flow | 1 | -1 | 2 | 12 | -12 | -1 |
| Free cash flow | -1 | 5 | 0 | -24 | -12 | -8 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 90 | 70 | 69 | 52 | 86 | 83 |
| Inventory days | 95 | 81 | 109 | 102 | 129 | 122 |
| Days payable | 97 | 83 | 93 | 43 | 50 | 60 |
| Cash conversion cycle | 88 | 67 | 84 | 110 | 165 | 144 |
| Working capital days | 7 | 30 | 36 | 88 | 129 | 94 |
| Return on capital employed | 12.0% | 32.0% | 33.0% | 19.0% | 6.0% | 14.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Promoters hold 67.17% as of Sept 2026; institutions added 0.14 pts since Aug 2026.
since Aug 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
The same filing shows 1 holder trimming and 4 off the list — both are in the register beside this.
Named in the Sep 2026 filing
Every holder of Saakshi Medtech above SEBI's 1% disclosure line, and what changed since Aug 2026.
| Holder | Stake | Change |
|---|---|---|
| 59.49% | newly disclosed | |
| 4.45% | −0.53 pp | |
| 4.23% | newly disclosed | |
| 3.45% | newly disclosed | |
| 2.56% | +0.22 pp | |
| 1.20% | newly disclosed | |
| — | off the list | |
| — | off the list | |
| — | off the list | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Free account: one company. Everything above stays public.
Write why you follow Saakshi Medtech and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Guides on how to read this kind of business and the numbers that matter.
